TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants of either sex who have reached at least 42 days (6 weeks) of age and not more than 56 days (8 weeks) of age at the time of enrollment~* Born at full term of pregnancy (Gestational age ≥37 weeks)~* Body weight ≥ 3.2 kg at the time of screening~* Born to HIV negative mother~* The parents or Legally Acceptable Representative (LAR) able to understand and comply with planned study procedures~* Signed informed consent by subject's parents or Legally Acceptable Representative (LAR)~Exclusion Criteria:~* Previously received any polio vaccines (OPV or IPV)~* History of previous or concurrent vaccinations other than HepB, BCG, DTP, Hib, Rotavirus vaccine and PCV~* History of bleeding disorder contraindicating intramuscular injection.~* Experienced fever ≥ 38 °C/ 100.4 °F within the past 3 days prior to the screening~* Receipt of immunoglobulin or blood-derived product since birth~* History of allergic reactions to any vaccine components, including excipients and preservatives (neomycin, streptomycin and polymyxin B, etc.)~* Known or suspected immune disorder, or received immunosuppressive therapy~* History of poliomyelitis~* History of any neurological disorders or seizures~* Known or suspected febrile, acute or progressive illness~* Household contact and/or intimate exposure in the previous 30 days to an individual with poliomyelitis~* Participation in another interventional trial within 30 days before to the enrollment or simultaneous participation in another clinical study~* Infants whose families are planning to leave the area of the study site before the end of the study period~* Infants who is considered unsuitable for the clinical study by the investigator

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- Test group 1 (Type: EXPERIMENTAL): Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
- Test group 2 (Type: EXPERIMENTAL): Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
- Test group 3 (Type: EXPERIMENTAL): High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
- Comparator (Type: ACTIVE_COMPARATOR): Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment in Infant in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Resident of Kolokani, Mali~* Age less than 24 months~Exclusion Criteria:~* Not Resident of Kolokani~* Age of 24 months or above

- Gender: ALL
- Minimum Age: None
- Maximum Age: 23 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Applying Neuroprosthesis to Improve Grasping and Reaching in Spinal Cord Injury Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* traumatic spinal cord lesion between C4 and C7(incomplete)~* participants will be recruited during the first six months post-SCI.~Exclusion Criteria:~* uncontrolled hypertension~* susceptibility to autonomic dysreflexia~* pressure ulcer~* cardiac pacemakers~* skin rush

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Occupational Therapy (COT) (Type: ACTIVE_COMPARATOR): Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
- Neuroprosthesis-FES Therapy (Type: EXPERIMENTAL): The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* singleton gestation~* maternal age as indication to fetal karyotyping~Exclusion Criteria:~* consumption of drugs interfering with the immune system~* previous miscarriages~* pregnancy at risk for maternal or fetal disease~* lactose intolerance

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- controls (Type: NO_INTERVENTION): The patients will be not treated with vaginal lactoferrin
- Lactoferrin (Type: ACTIVE_COMPARATOR): The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing IFN Beta - 1B Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained.~2. Age between 18 and 50 years inclusive.~3. Male and female patients.~4. Clinically definite or laboratory supported definite RR MS (Poser et al, 1983) for not less than 2 year.~5. Two clinically documented relapses during the preceding 24 months.~6. No relapse or relapse related neurological deterioration for at least 30 days prior to entry in the study.~7. Patients EDSS score from 1 to 3.5 (probably to be extended to 5.5).~8. MRI activity. At least one enhancing lesion during the baseline MRI run-in study .~9. Women capable of having children must agree to use adequate con-traceptive methods (condoms with spermicides, IUCD, oral contraceptives or other adequate barrier contraception).~10. Caregivers agreement to assist the patient to comply with study requirements, if neces-sary (e.g. study drug administration, visits to center).~Exclusion Criteria:~1. Any form of Multiple Sclerosis other than relapsing-remitting.~2. Any other disease which could better explain the patient's signs and symptoms.~3. Any other disabling condition, which could interfere with the clinical evaluation.~4. Pregnancy or lactation.~5. Medical psychiatric, or other conditions that compromise patient's ability to give informed consent, to comply with the trial protocol, or to complete the study.~6. Alcohol or drug abuse in the 90 days preceding screening visit.~7. Uncontrolled clinically significant heart diseases, i.e., cardiac arrhythmias, uncon-trolled angina pectoris, uncompensated congestive heart failure~8. Clinically significant liver, renal and bone marrow dysfunction as defined by the ran-ges of laboratory evaluations. The following ranges (see table 1) for key laboratory evaluations will be considered as adequate for inclusion:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients meeting ACC/AHA criteria for paroxysmal atrial fibrillation (episodes typically last no more than 7 days and are self-terminating)~* Eligible for pulmonary vein isolation~* Able to tolerate antiarrhythmic medication~Exclusion Criteria:~* Age \<18~* Persistent or permanent atrial fibrillation (episodes last \>7 days and require cardioversion)~* Antiarrhythmic treatment for indication other than atrial fibrillation~* Contraindication or intolerance to all antiarrhythmic medications~* Primary physician unwilling to withhold antiarrhythmic drugs for duration of the study~* Failure to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AAD:YES (Type: OTHER): Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
- AAD:NO (Type: OTHER): Subjects do not receive membrane-active anti-arrhythmic medications after ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of BIS for Quantification of Lymphedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed invasive or in-situ carcinoma of the breast~* Participants must have undergone sentinel node mapping or axillary dissection~* Life expectancy of greater than 1 year.~* Willingness to comply with required follow up Perometer and BIS measurements and completion of LEFT-BC questionnaire~Exclusion Criteria:~* Patients who have known metastatic disease or other locally advanced disease in the thoracic or cervical regions~* Any patient who will not be returning routinely for follow-up at MGH or DFHCC~* Participants with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events~* History of primary lymphedema~* History of prior surgery or radiation to the head, neck, upper limb, or trunk~* Participants who have evidence that axillary lymph node malignancy is causing lymphedema due to recurrence as per physician discretion~* Any patient who has bilateral lymph node mapping or dissection~* Any patient with a current case of cellulitis~* Patients with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIS (Type: None): Subjects evaluated using Bioimpedance Spectroscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anal HSIL confirmed by biopsy no more than 30 days prior to entry~* Anal HSIL deemed not amenable to therapy or participant declines routine ablative therapy~* HIV positive~* Stable HIV treatment regimen for at least 8 weeks prior to entry~* At least 18 years of age~* Women of childbearing potential must use contraception~* Platelet count above 70,000/mm3 within 30 days prior to entry~* ANC greater or equal to 1000/mm3 within 30 days prior to entry~* Creatinine less then or equal to 1.5 times ULN within 30 days prior to entry~* AST and ALT less than or equal to 3 times ULN within 30 days prior to entry~Exclusion Criteria:~* Prior history of invasive anal, cervical, vaginal, or vulvar cancer~* Pregnancy or lactation and breast-feeding~* Must not participate in a conception process including sperm donation~* Medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with ability to comply with protocol~* Known allergy to any topical cream components~* Patients with lesions clinically suspicious per HRA examiner for early progression (less than one year) to anal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, African American (self-reported), ≥12 years of age~* Moderate to severe asthma requiring treatment with an inhaled corticosteroid~* Diagnosis of asthma for at least 6 months~Exclusion Criteria:~* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)~* Any significant disease or disorder that may jeopardize a subject's safety

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symbicort (Type: EXPERIMENTAL): Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
- Budesonide (Type: EXPERIMENTAL): Budesonide HFA pMDI 160 ug x 2 actuations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients being treated with a maintenance dose of 75 mg clopidogrel and 100 mg aspirin daily after previous PCI with coronary stenting were included in the study. All patients received standardized therapy with a loading dose of 600 mg of clopidogrel hydrogen sulfate and 400 mg aspirin.~All participants had a normal platelet count (150,000-450,000/mL).~Exclusion Criteria:~* Patients with severe liver disorders, current gastrointestinal disorders, a current infection, congestive heart failure, or a known bleeding disorder as well as patients on bivalirudin or glycoprotein IIb/III antagonists within the last 7 days were excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Pantoprazole (Type: ACTIVE_COMPARATOR): Drug: Pantoprazole 40 mg once-daily
- Ranitidine (Type: EXPERIMENTAL): Drug: Ranitidine 150 mg twice-daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervention to Improve Adherence in Teen Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects age 11 - 24 years~* At least 3 months post kidney transplant~Exclusion Criteria:~* Significant neurocognitive disabilities limiting the subject's ability to understand and participate on their own~* Unable to communicate in English or French (Montreal site)~* Unable to communicate in English (all other sites)

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Multi-component Intervention (Type: EXPERIMENTAL): Multi-component Intervention consisting of:~* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~* text message, email, or visual cue dose reminders
- Attention control (Type: NO_INTERVENTION): Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females between 18-35 years old~* In need of EC (had unprotected intercourse within 120 hours - 5 days)~* Desire to prevent pregnancy for 1 year~* Fluent in English and/or Spanish~* Have a regular menstrual cycle (21-35 days)~* Know their last menstrual period (+/-3 days)~* Be willing to comply with the study requirements~* Desire to initiate an IUD~* Negative urine pregnancy test~Exclusion Criteria:~* Current pregnancy~* Breastfeeding~* Intrauterine infection within the past three months~* Sterilization~* Already have an IUD or contraception implant (Nexplanon) in place~* Vaginal bleeding of unknown etiology~* Known Gonorrhea or Chlamydia infection in the last 30 days (unless successfully treated at least 7 days prior to study entry)~* Known abnormalities of the uterus that distort the uterine cavity~* Allergy to copper~* Use of oral Emergency Contraception in the preceeding 5 days

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Copper T380 IUD (Type: ACTIVE_COMPARATOR): Randomized to copper T380 IUD for EC (emergency contraception)
- LNG20 IUD (Type: ACTIVE_COMPARATOR): Randomized to LNG20 IUD for EC (emergency contraception)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pathologically confirmed adenocarcinoma of the pancreas.~* Patients will have unresectable disease, defined radiographically as \>180 degrees involvement of the superior mesenteric artery or celiac trunk or SMV/portal vein impingement that cannot be surgically reconstructed, in the absence of distant metastasis..~* Patients must have a Zubrod performance status (measure of general well being that ranges from 0 to 5 where 0 represents perfect health) of \< 2.~* Patients must have adequate organ function defined as follows: absolute neutrophil count of ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum creatinine ≤ 2 mg/dl, total bilirubin ≤ 3, (with relief of biliary obstruction if present (PTC tube or endobiliary stent)) and AST \< 5 times the upper limit of normal.~* Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial. Patients must not be breastfeeding.~* Patients must be aware of the investigational nature of the therapy and provide written informed consent.~* Patients must be at least 18 years old.~Exclusion Criteria:~* Other serious uncontrolled concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy.~* A history of previous chemotherapy for pancreatic cancer or abdominal radiation therapy.~* The use of any investigational agent in the month before enrollment into the study.~* Inability to discontinue a prescription or non-prescription drugs or other products known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 prior to Day 1 of dosing and to withhold throughout the study until 2 weeks after the last dose of study medication. Medications of particular concern are the following inhibitors of CYP3A4: azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole), macrolide antibiotics (erythromycin, clarithromycin), cimetidine, aprepitant, HIV protease inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin, barbiturates and rifampicin. Substrates of CYP3A4 include statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and cisapride.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-1775/ Gemcitabine/ Radiation Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete